Zobrazeno 1 - 10
of 824
pro vyhledávání: '"Multiple myeloma(MM)"'
Publikováno v:
Current Issues in Molecular Biology, Vol 46, Iss 8, Pp 8197-8208 (2024)
Multiple myeloma (MM) first-line treatment algorithms include immuno-chemotherapy (ICT) induction, high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) consolidation, followed by lenalidomide maintenance. After these initial thera
Externí odkaz:
https://doaj.org/article/5fa5f48e35e143108164d9f97ffef067
Autor:
Mengyao Hu, Yipei Song, Chunhua Yang, Jiazhao Wang, Wei Zhu, Ao Kan, Pei Yang, Jiankun Dai, Honghui Yu, Lianggeng Gong
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract The aim of this study is to assess the effectiveness of conventional and two additional functional markers derived from standard cardiac magnetic resonance (CMR) images in detecting the occurrence of late gadolinium enhancement (LGE) in pati
Externí odkaz:
https://doaj.org/article/13f7c38f210b44a4a9d0e4b1c31a35da
Autor:
Michaël Constantinides, Nicolas Robert, Caroline Multrier, Loïs Coënon, Mauricio Campos-Mora, Carine Jacquard, Fei Gao, Sara Zemiti, Jessy Presumey, Guillaume Cartron, Jérome Moreaux, Martin Villalba
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
FCGR3A presents a single nucleotide polymorphism at location 158 (V/F), which affects its binding to the fragment crystallizable (Fc) of antibodies (Abs). FcγRIIIa-158 V allotype has the highest affinity and is associated with a better clinical resp
Externí odkaz:
https://doaj.org/article/41bd2ee094e54a0abe73a44b834b684b
Autor:
Omar S. Al-Odat, Weam Othman Elbezanti, Krishne Gowda, Sandeep K. Srivastava, Shantu G. Amin, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Despite a record number of clinical studies investigating various anti-myeloma treatments, the 5-year survival rate for multiple myeloma (MM) patients in the US is only 55%, and almost all patients relapse. Poor patient outcomes demonstrate that myel
Externí odkaz:
https://doaj.org/article/63ddb4eafebe460cae46dd670075e26e
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-8 (2024)
Abstract Multiple myeloma (MM) denotes a cancerous growth characterized by abnormal proliferation of plasma cells. Growing evidence suggests that the complexity in addressing MM lies in the presence of minimal residual disease (MRD) within the body.
Externí odkaz:
https://doaj.org/article/738a5890f35448639e73d78c7f7f6e75
Autor:
Disi Zhang, Dong Zhan, Rui Zhang, Yunyan Sun, Ci Duan, Jiapeng Yang, Jia Wei, Xianshi Li, Yanqi Lu, Xun Lai
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Multiple myeloma (MM) progression involves diminished tumor antigen presentation and an immunosuppressive microenvironment, characterized by diminished expression of major histocompatibility complexes (MHC) class I molecule and elevated prog
Externí odkaz:
https://doaj.org/article/95ae17e8a1b2432485085590b7ac439b
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Multiple myeloma (MM) is a hematological cancer marked by plasma cell accumulation in the bone marrow. Despite treatment advancements, MM remains incurable in most patients. MM-associated immune dysregulation fosters disease progression, prompting re
Externí odkaz:
https://doaj.org/article/5fd886a9599348fdb6af9e263f0f2545
Autor:
Yu Lu, Chaohui Zheng, Wenxia Zhang, Xuan Liu, Ziwei Zhou, Zhenzhen Wang, Huan Hua, Zhengrong Song, Xuejun Zhang, Shuyi Liu, Leisheng Zhang, Fuxu Wang
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Background Mesenchymal stem/stromal cells (MSCs) have been acknowledged as the most important stromal cells in the bone marrow (BM) microenvironment for physiologic hematopoiesis and the concomitant hematologic malignancies. However, the sys
Externí odkaz:
https://doaj.org/article/6a09c832414e4a1897b0d796b120f689
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-16 (2024)
Abstract Background The incidence of multiple myeloma (MM), a type of blood cancer affecting monoclonal plasma cells, is rising. Although new drugs and therapies have improved patient outcomes, MM remains incurable. Recent studies have highlighted th
Externí odkaz:
https://doaj.org/article/8a3eb6f76cac49539141ad27207478f0
Publikováno v:
Zhongguo shuxue zazhi, Vol 37, Iss 2, Pp 151-157 (2024)
Objective To explore the feasibility of blood transfusion compatibility testing for multiple myeloma(MM) patients treated with anti-CD38 monoclonal antibody daratumumab (DARA) after DARA-Fab fragment blocking, and to evaluate the transfusion efficacy
Externí odkaz:
https://doaj.org/article/3f8887103ece46a6b46de2f7d62db080